Free Trial
NASDAQ:ELTX

Elicio Therapeutics Q3 2023 Earnings Report

Elicio Therapeutics EPS Results

Actual EPS
-$1.27
Consensus EPS
-$0.80
Beat/Miss
Missed by -$0.47
One Year Ago EPS
N/A

Elicio Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elicio Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Wednesday, November 8, 2023
Conference Call Time
6:00PM ET

Earnings Documents

Elicio Therapeutics Earnings Headlines

Elicio Therapeutics reports FY24 EPS ($4.25) vs ($6.96) last year
Trump's Neighbor Issues Urgent Financial Warning: "The Economic Singularity Is Coming"
They call me "The Seer of Wall Street" for a reason. When I warned about Enron in 2001, most analysts were still rating it a "buy." When I developed my system, the financial establishment scoffed — until my system began outperforming nearly every fund manager on the Street.
See More Elicio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elicio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elicio Therapeutics and other key companies, straight to your email.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

View Elicio Therapeutics Profile

More Earnings Resources from MarketBeat